Kezar Life Sciences (NASDAQ:KZR) Announces Quarterly Earnings Results, Misses Expectations By $0.06 EPS

Kezar Life Sciences (NASDAQ:KZR) released its earnings results on Tuesday. The company reported ($2.77) earnings per share for the quarter, missing analysts’ consensus estimates of ($2.71) by ($0.06), Zacks reports.

Kezar Life Sciences Stock Performance

Shares of Kezar Life Sciences stock opened at $5.64 on Wednesday. The business’s fifty day simple moving average is $6.07 and its 200-day simple moving average is $6.71. The company has a quick ratio of 7.65, a current ratio of 7.65 and a debt-to-equity ratio of 0.05. The firm has a market cap of $41.15 million, a PE ratio of -0.43 and a beta of 0.49. Kezar Life Sciences has a 52 week low of $5.20 and a 52 week high of $9.53.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on KZR shares. William Blair reaffirmed an “outperform” rating on shares of Kezar Life Sciences in a report on Friday, February 28th. HC Wainwright reissued a “neutral” rating on shares of Kezar Life Sciences in a report on Monday, December 2nd. Finally, Wells Fargo & Company decreased their target price on shares of Kezar Life Sciences from $11.00 to $9.00 and set an “equal weight” rating on the stock in a report on Thursday, December 19th.

Kezar Life Sciences Company Profile

Kezar Life Sciences, Inc, a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis.